Literature DB >> 19256309

Update on the natural history and systemic treatment of psoriasis.

Stephen K Richardson1, Joel M Gelfand.   

Abstract

The onset of psoriatic disease and its associated comorbidities involves the interplay among a myriad of genetic and environmental risk factors. As we gain further insight into the immunopathogenesis of psoriasis, we hope it will provide the basis for the development of safer, more efficacious, and more durable therapeutics in the future. Given its enormous toll on patient health and quality of life, steps should be taken to prevent or decrease the risk for psoriasis-associated comorbidities through behavior modification and use of preventative health screenings and treatments. Future studies will need to be performed to determine if successful treatment of psoriasis will lead to a decreased risk for developing psoriasis-associated comorbidities over time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19256309      PMCID: PMC2634854          DOI: 10.1016/j.yadr.2008.09.006

Source DB:  PubMed          Journal:  Adv Dermatol        ISSN: 0882-0880


  123 in total

1.  The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.

Authors:  H Devrimci-Ozguven; T N Kundakci; H Kumbasar; A Boyvat
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-07       Impact factor: 6.166

Review 2.  Clinical considerations of efalizumab therapy in patients with psoriasis.

Authors:  Tiffani K Hamilton
Journal:  Semin Cutan Med Surg       Date:  2005-03

3.  The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.

Authors:  M Shbeeb; K M Uramoto; L E Gibson; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

4.  Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention.

Authors:  Gerald H Mazurek; Margarita E Villarino
Journal:  MMWR Recomm Rep       Date:  2003-01-31

5.  Psoriasis and alexithymia.

Authors:  D Vidoni; E Campiutti; R D'Aronco; M De Vanna; E Aguglia
Journal:  Acta Derm Venereol Suppl (Stockh)       Date:  1989

6.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Authors:  Alan Menter; Steven R Feldman; Gerald D Weinstein; Kim Papp; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Cynthia Arnold; Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2006-09-06       Impact factor: 11.527

7.  Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.

Authors:  Frank A Parke; John D Reveille
Journal:  Arthritis Rheum       Date:  2004-10-15

8.  Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.

Authors:  Daniel Creamer; Michael Allen; Rhys Jaggar; Richard Stevens; Roy Bicknell; Jonathan Barker
Journal:  Arch Dermatol       Date:  2002-06

9.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

10.  Suicidal ideation in psoriasis.

Authors:  M A Gupta; N J Schork; A K Gupta; S Kirkby; C N Ellis
Journal:  Int J Dermatol       Date:  1993-03       Impact factor: 2.736

View more
  13 in total

1.  Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need.

Authors:  Alexis Ogdie; Joel M Gelfand
Journal:  Arch Dermatol       Date:  2010-07

Review 2.  Psoriasis: what we have learned from mouse models.

Authors:  Erwin F Wagner; Helia B Schonthaler; Juan Guinea-Viniegra; Erwin Tschachler
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

3.  Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment.

Authors:  Tom C Chan; Jason E Hawkes; James G Krueger
Journal:  Ther Adv Chronic Dis       Date:  2018-03-19       Impact factor: 5.091

Review 4.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

5.  Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Authors:  Joel M Gelfand; Joy Wan; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Michael B Stierstorfer; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Andrea B Troxel; Daniel B Shin; Jane M Steinemann; Jennifer Goldfarb; Howa Yeung; Abby S Van Voorhees
Journal:  Arch Dermatol       Date:  2012-04

6.  Modulation of psoriatic-like skin inflammation by traditional Indian medicine Divya-Kayakalp-Vati and Oil through attenuation of pro-inflammatory cytokines.

Authors:  Acharya Balkrishna; Sachin Sakat; Kheemraj Joshi; Rani Singh; Sudeep Verma; Pardeep Nain; Kunal Bhattacharya; Anurag Varshney
Journal:  J Tradit Complement Med       Date:  2021-09-20

7.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

Review 8.  Psoriasis and metabolic disease: epidemiology and pathophysiology.

Authors:  Rahat S Azfar; Joel M Gelfand
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

9.  CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis.

Authors:  Søren Ulrik Sønder; Andrea Paun; Hye-Lin Ha; Peter F Johnson; Ulrich Siebenlist
Journal:  J Immunol       Date:  2012-05-11       Impact factor: 5.422

10.  TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier.

Authors:  Byung Eui Kim; Michael D Howell; Emma Guttman-Yassky; Emma Guttman; Patricia M Gilleaudeau; Irma R Cardinale; Mark Boguniewicz; James G Krueger; Donald Y M Leung
Journal:  J Invest Dermatol       Date:  2011-02-24       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.